Validation pour Ingenuity254

vers la météo de la validation par utilisateur

Ingenuity254

precedent - 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 - suivant

Phrase 48 - PMID ?

In liver from adult SP , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of SP NODE protein .

Non annotée
Je ne sais pas
Je n'ai pas trouvé d'analyse satisfaisante

Commentaires :

Analyse 0

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 |            +----------------------APPOS---------------------+COMP:N-N(o+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
APPOS (CFAM,period)
COMP:N-N(of) (dosage,1g/100g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 1

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 |            +----------------------APPOS---------------------+COMP:N-N(o+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
APPOS (CFAM,period)
COMP:N-N(of) (dosage,1g/100g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 2

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 +----------------------------APPOS----------------------------+COMP:N-N(o+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
APPOS (administration,period)
COMP:N-N(of) (dosage,1g/100g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 3

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+         +-------COMP:N-N(of)-------+     
      |                 |                 |            +----------------------APPOS---------------------+COMP:N-N(o+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
APPOS (CFAM,period)
COMP:N-N(of) (dosage,1g/100g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 4

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+         +-------COMP:N-N(of)-------+     
      |                 |                 |            +----------------------APPOS---------------------+COMP:N-N(o+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
APPOS (CFAM,period)
COMP:N-N(of) (dosage,1g/100g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 5

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 +----------------------------APPOS----------------------------+COMP:N-N(o+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
APPOS (administration,period)
COMP:N-N(of) (dosage,1g/100g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 6

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+         +-------COMP:N-N(of)-------+     
      |                 |                 +----------------------------APPOS----------------------------+COMP:N-N(o+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
APPOS (administration,period)
COMP:N-N(of) (dosage,1g/100g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 7

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+         +-------COMP:N-N(of)-------+     
      |                 |                 +----------------------------APPOS----------------------------+COMP:N-N(o+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
APPOS (administration,period)
COMP:N-N(of) (dosage,1g/100g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 8

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                                   |                                     +-----------COMP:N-N(of)-----------+         |         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 |                           +-----------COMP:N-N(of)----------+COMP:N-N(o+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (1g/100g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 9

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                                   |                                     +-----------COMP:N-N(of)-----------+         |         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 |                           +-----------COMP:N-N(of)----------+COMP:N-N(o+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (1g/100g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 10

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 |                                                             +COMP:N-N(o+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
COMP:N-N(of) (dosage,1g/100g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 11

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 |                                                             +COMP:N-N(o+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
COMP:N-N(of) (dosage,1g/100g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 12

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                                   |                                     +-----------COMP:N-N(of)-----------+         |         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 |                           +-----------COMP:N-N(of)----------+COMP:N-N(o+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (1g/100g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 13

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                 |                 |                                     +-----------COMP:N-N(of)-----------+         |         +-------COMP:N-N(of)-------+     
      |                 |                 |                           +-----------COMP:N-N(of)----------+COMP:N-N(o+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (1g/100g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 14

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                 |                 |                                     +-----------COMP:N-N(of)-----------+         |         +-------COMP:N-N(of)-------+     
      |                 |                 |                           +-----------COMP:N-N(of)----------+COMP:N-N(o+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (1g/100g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 15

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                                   |                                     +-----------COMP:N-N(of)-----------+         |         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 |                           +-----------COMP:N-N(of)----------+COMP:N-N(o+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (1g/100g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 16

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 |                                                             +COMP:N-N(o+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
COMP:N-N(of) (dosage,1g/100g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 17

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                                   |                           +----------------COMP:N-N(of)----------------+         |         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 |                           +-----------COMP:N-N(of)----------+          |         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 18

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+         +-------COMP:N-N(of)-------+     
      |                 |                 |                                                             +COMP:N-N(o+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
COMP:N-N(of) (dosage,1g/100g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 19

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                                   |                           +----------------COMP:N-N(of)----------------+         |         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 |                           +-----------COMP:N-N(of)----------+          |         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 20

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+         +-------COMP:N-N(of)-------+     
      |                 |                 |                                                             +COMP:N-N(o+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
COMP:N-N(of) (dosage,1g/100g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 21

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 |                                                             +COMP:N-N(o+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
COMP:N-N(of) (dosage,1g/100g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 22

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                 |                 |                                     +-----------COMP:N-N(of)-----------+         |         +-------COMP:N-N(of)-------+     
      |                 |                 |                           +-----------COMP:N-N(of)----------+COMP:N-N(o+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (1g/100g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 23

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                 |                 |                                     +-----------COMP:N-N(of)-----------+         |         +-------COMP:N-N(of)-------+     
      |                 |                 |                           +-----------COMP:N-N(of)----------+COMP:N-N(o+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (1g/100g,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 24

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                                   |                           +----------------COMP:N-N(of)----------------+         |         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 |                           +-----------COMP:N-N(of)----------+          |         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 25

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+         +-------COMP:N-N(of)-------+     
      |                 |                 |                                                             +COMP:N-N(o+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
COMP:N-N(of) (dosage,1g/100g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 26

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                 |                 |                           +----------------COMP:N-N(of)----------------+         |         +-------COMP:N-N(of)-------+     
      |                 |                 |                           +-----------COMP:N-N(of)----------+          |         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 27

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                 |                 |                           +----------------COMP:N-N(of)----------------+         |         +-------COMP:N-N(of)-------+     
      |                 |                 |                           +-----------COMP:N-N(of)----------+          |         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 28

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                                   |                           +----------------COMP:N-N(of)----------------+         |         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 |                           +-----------COMP:N-N(of)----------+          |         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 29

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+         +-------COMP:N-N(of)-------+     
      |                 |                 |                                                             +COMP:N-N(o+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
COMP:N-N(of) (dosage,1g/100g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 30

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                 |                 |                           +----------------COMP:N-N(of)----------------+         |         +-------COMP:N-N(of)-------+     
      |                 |                 |                           +-----------COMP:N-N(of)----------+          |         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 31

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                 |                 |                           +----------------COMP:N-N(of)----------------+         |         +-------COMP:N-N(of)-------+     
      |                 |                 |                           +-----------COMP:N-N(of)----------+          |         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,week)
MOD_ATT:N-N (period,treatment)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 32

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 |                           +-----------COMP:N-N(of)----------+COMP:N-N(o+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 33

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 |                           +-----------COMP:N-N(of)----------+COMP:N-N(o+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 34

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 |                           +-----------COMP:N-N(of)----------+COMP:N-N(o+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 35

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+         +-------COMP:N-N(of)-------+     
      |                 |                 |                           +-----------COMP:N-N(of)----------+COMP:N-N(o+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 36

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+         +-------COMP:N-N(of)-------+     
      |                 |                 |                           +-----------COMP:N-N(of)----------+COMP:N-N(o+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 37

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 |                           +-----------COMP:N-N(of)----------+COMP:N-N(o+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 38

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+         +-------COMP:N-N(of)-------+     
      |                 |                 |                           +-----------COMP:N-N(of)----------+COMP:N-N(o+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 39

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+         +-------COMP:N-N(of)-------+     
      |                 |                 |                           +-----------COMP:N-N(of)----------+COMP:N-N(o+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+              +COMP:N-N(+              +MOD_ATT:+      +MOD+         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |              |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 40

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 |                   +-----------------------OBJ:V-N----------------------+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+      |       +COMP:N-N(+              +MOD_ATT:+COMP:N+   |         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |      |       |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
OBJ:V-N (with,week)
COMP:N-N(of) (dosage,1g/100g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 41

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 |                   +-----------------------OBJ:V-N----------------------+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+      |       +COMP:N-N(+              +MOD_ATT:+COMP:N+   |         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |      |       |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
OBJ:V-N (with,week)
COMP:N-N(of) (dosage,1g/100g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 42

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 |                   +-----------------------OBJ:V-N----------------------+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+      |       +COMP:N-N(+              +MOD_ATT:+COMP:N+   |         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |      |       |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
OBJ:V-N (with,week)
COMP:N-N(of) (dosage,1g/100g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 43

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+         +-------COMP:N-N(of)-------+     
      |                 |                 |                   +-----------------------OBJ:V-N----------------------+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+      |       +COMP:N-N(+              +MOD_ATT:+COMP:N+   |         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |      |       |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
OBJ:V-N (with,week)
COMP:N-N(of) (dosage,1g/100g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 44

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+         +-------COMP:N-N(of)-------+     
      |                 |                 |                   +-----------------------OBJ:V-N----------------------+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+      |       +COMP:N-N(+              +MOD_ATT:+COMP:N+   |         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |      |       |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
OBJ:V-N (with,week)
COMP:N-N(of) (dosage,1g/100g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 45

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 |                   +-----------------------OBJ:V-N----------------------+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+      |       +COMP:N-N(+              +MOD_ATT:+COMP:N+   |         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |      |       |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
OBJ:V-N (with,week)
COMP:N-N(of) (dosage,1g/100g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 46

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+         +-------COMP:N-N(of)-------+     
      |                 |                 |                   +-----------------------OBJ:V-N----------------------+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+      |       +COMP:N-N(+              +MOD_ATT:+COMP:N+   |         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |      |       |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
OBJ:V-N (with,week)
COMP:N-N(of) (dosage,1g/100g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 47

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+         +-------COMP:N-N(of)-------+     
      |                 |                 |                   +-----------------------OBJ:V-N----------------------+         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+      |       +COMP:N-N(+              +MOD_ATT:+COMP:N+   |         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |      |       |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
OBJ:V-N (with,week)
COMP:N-N(of) (dosage,1g/100g)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 48

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                                   |                   +-----------------------OBJ:V-N----------------------+         |                                          
      |                                   |                   |       +-----------COMP:N-N(of)----------+          |         |         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 |                   |       |         +---------COMP:N-N(of)---------+   |         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+      |       +COMP:N-N(+              +MOD_ATT:+COMP:N+   |         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |      |       |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
OBJ:V-N (with,week)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (1g/100g,2)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 49

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                                   |                   +-----------------------OBJ:V-N----------------------+         |                                          
      |                                   |                   |       +-----------COMP:N-N(of)----------+          |         |         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 |                   |       |         +---------COMP:N-N(of)---------+   |         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+      |       +COMP:N-N(+              +MOD_ATT:+COMP:N+   |         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |      |       |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
OBJ:V-N (with,week)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (1g/100g,2)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 50

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                                   |                   +-----------------------OBJ:V-N----------------------+         |                                          
      |                                   |                   |       +-----------COMP:N-N(of)----------+          |         |         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 |                   |       |         +---------COMP:N-N(of)---------+   |         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+      |       +COMP:N-N(+              +MOD_ATT:+COMP:N+   |         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |      |       |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
OBJ:V-N (with,week)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (1g/100g,2)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 51

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                 |                 |                   +-----------------------OBJ:V-N----------------------+         |                                          
      |                 |                 |                   |       +-----------COMP:N-N(of)----------+          |         |         +-------COMP:N-N(of)-------+     
      |                 |                 |                   |       |         +---------COMP:N-N(of)---------+   |         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+      |       +COMP:N-N(+              +MOD_ATT:+COMP:N+   |         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |      |       |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
OBJ:V-N (with,week)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (1g/100g,2)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 52

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                 |                 |                   +-----------------------OBJ:V-N----------------------+         |                                          
      |                 |                 |                   |       +-----------COMP:N-N(of)----------+          |         |         +-------COMP:N-N(of)-------+     
      |                 |                 |                   |       |         +---------COMP:N-N(of)---------+   |         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+      |       +COMP:N-N(+              +MOD_ATT:+COMP:N+   |         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |      |       |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
OBJ:V-N (with,week)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (1g/100g,2)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 53

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                                   |                   +-----------------------OBJ:V-N----------------------+         |                                          
      |                                   |                   |       +-----------COMP:N-N(of)----------+          |         |         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 |                   |       |         +---------COMP:N-N(of)---------+   |         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+      |       +COMP:N-N(+              +MOD_ATT:+COMP:N+   |         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |      |       |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
OBJ:V-N (with,week)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (1g/100g,2)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 54

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                                   |                   +-----------------------OBJ:V-N----------------------+         |                                          
      |                                   |                   |       +--------------COMP:N-N(of)--------------+   |         |         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 |                   |       +-----------COMP:N-N(of)----------+      |   |         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+      |       +COMP:N-N(+              +MOD_ATT:+      |   |         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |      |       |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
OBJ:V-N (with,week)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,2)
MOD_ATT:N-N (period,treatment)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 55

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                                   |                   +-----------------------OBJ:V-N----------------------+         |                                          
      |                                   |                   |       +--------------COMP:N-N(of)--------------+   |         |         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 |                   |       +-----------COMP:N-N(of)----------+      |   |         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+      |       +COMP:N-N(+              +MOD_ATT:+      |   |         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |      |       |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
OBJ:V-N (with,week)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,2)
MOD_ATT:N-N (period,treatment)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 56

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                 |                 |                   +-----------------------OBJ:V-N----------------------+         |                                          
      |                 |                 |                   |       +-----------COMP:N-N(of)----------+          |         |         +-------COMP:N-N(of)-------+     
      |                 |                 |                   |       |         +---------COMP:N-N(of)---------+   |         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+      |       +COMP:N-N(+              +MOD_ATT:+COMP:N+   |         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |      |       |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
OBJ:V-N (with,week)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (1g/100g,2)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 57

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                 |                 |                   +-----------------------OBJ:V-N----------------------+         |                                          
      |                 |                 |                   |       +-----------COMP:N-N(of)----------+          |         |         +-------COMP:N-N(of)-------+     
      |                 |                 |                   |       |         +---------COMP:N-N(of)---------+   |         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+      |       +COMP:N-N(+              +MOD_ATT:+COMP:N+   |         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |      |       |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
OBJ:V-N (with,week)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (1g/100g,2)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 58

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                                   |                   +-----------------------OBJ:V-N----------------------+         |                                          
      |                                   |                   |       +--------------COMP:N-N(of)--------------+   |         |         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 |                   |       +-----------COMP:N-N(of)----------+      |   |         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+      |       +COMP:N-N(+              +MOD_ATT:+      |   |         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |      |       |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
OBJ:V-N (with,week)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,2)
MOD_ATT:N-N (period,treatment)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 59

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                 |                 |                   +-----------------------OBJ:V-N----------------------+         |                                          
      |                 |                 |                   |       +--------------COMP:N-N(of)--------------+   |         |         +-------COMP:N-N(of)-------+     
      |                 |                 |                   |       +-----------COMP:N-N(of)----------+      |   |         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+      |       +COMP:N-N(+              +MOD_ATT:+      |   |         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |      |       |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
OBJ:V-N (with,week)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,2)
MOD_ATT:N-N (period,treatment)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 60

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                 |                 |                   +-----------------------OBJ:V-N----------------------+         |                                          
      |                 |                 |                   |       +--------------COMP:N-N(of)--------------+   |         |         +-------COMP:N-N(of)-------+     
      |                 |                 |                   |       +-----------COMP:N-N(of)----------+      |   |         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+      |       +COMP:N-N(+              +MOD_ATT:+      |   |         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |      |       |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
OBJ:V-N (with,week)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,2)
MOD_ATT:N-N (period,treatment)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 61

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                                   |                   +-----------------------OBJ:V-N----------------------+         |                                          
      |                                   |                   |       +--------------COMP:N-N(of)--------------+   |         |         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 |                   |       +-----------COMP:N-N(of)----------+      |   |         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+      |       +COMP:N-N(+              +MOD_ATT:+      |   |         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |      |       |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
OBJ:V-N (with,week)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,2)
MOD_ATT:N-N (period,treatment)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 62

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                 |                 |                   +-----------------------OBJ:V-N----------------------+         |                                          
      |                 |                 |                   |       +--------------COMP:N-N(of)--------------+   |         |         +-------COMP:N-N(of)-------+     
      |                 |                 |                   |       +-----------COMP:N-N(of)----------+      |   |         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+      |       +COMP:N-N(+              +MOD_ATT:+      |   |         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |      |       |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
OBJ:V-N (with,week)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,2)
MOD_ATT:N-N (period,treatment)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 63

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                 |                 |                   +-----------------------OBJ:V-N----------------------+         |                                          
      |                 |                 |                   |       +--------------COMP:N-N(of)--------------+   |         |         +-------COMP:N-N(of)-------+     
      |                 |                 |                   |       +-----------COMP:N-N(of)----------+      |   |         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+      |       +COMP:N-N(+              +MOD_ATT:+      |   |         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |      |       |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
OBJ:V-N (with,week)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
COMP:N-N(of) (dosage,2)
MOD_ATT:N-N (period,treatment)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 64

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                                   |                   +-----------------------OBJ:V-N----------------------+         |         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 |                   |       +-----------COMP:N-N(of)----------+          |         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+      |       +COMP:N-N(+              +MOD_ATT:+COMP:N+   |         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |      |       |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
OBJ:V-N (with,week)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 65

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                                   |                   +-----------------------OBJ:V-N----------------------+         |         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 |                   |       +-----------COMP:N-N(of)----------+          |         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+      |       +COMP:N-N(+              +MOD_ATT:+COMP:N+   |         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |      |       |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
OBJ:V-N (with,week)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 66

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                                   |                   +-----------------------OBJ:V-N----------------------+         |         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 |                   |       +-----------COMP:N-N(of)----------+          |         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+      |       +COMP:N-N(+              +MOD_ATT:+COMP:N+   |         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |      |       |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
OBJ:V-N (with,week)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 67

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                 |                 |                   +-----------------------OBJ:V-N----------------------+         |         +-------COMP:N-N(of)-------+     
      |                 |                 |                   |       +-----------COMP:N-N(of)----------+          |         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+      |       +COMP:N-N(+              +MOD_ATT:+COMP:N+   |         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |      |       |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
OBJ:V-N (with,week)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 68

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                 |                 |                   +-----------------------OBJ:V-N----------------------+         |         +-------COMP:N-N(of)-------+     
      |                 |                 |                   |       +-----------COMP:N-N(of)----------+          |         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+      |       +COMP:N-N(+              +MOD_ATT:+COMP:N+   |         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |      |       |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
OBJ:V-N (with,week)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 69

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                                   +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                                   |                   +-----------------------OBJ:V-N----------------------+         |         +-------COMP:N-N(of)-------+     
      +--COMP:N-N(from)-+                 |                   |       +-----------COMP:N-N(of)----------+          |         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+      |       +COMP:N-N(+              +MOD_ATT:+COMP:N+   |         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |      |       |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
COMP:N-N(from) (liver,__SP__)
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
OBJ:V-N (with,week)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
COMP:V-N(In) (decrease,liver)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 70

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                 |                 |                   +-----------------------OBJ:V-N----------------------+         |         +-------COMP:N-N(of)-------+     
      |                 |                 |                   |       +-----------COMP:N-N(of)----------+          |         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+      |       +COMP:N-N(+              +MOD_ATT:+COMP:N+   |         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |      |       |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,CFAM)
OBJ:V-N (with,week)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)

Analyse 71

      +-----------------------------------------------------COMP:V-N(In)-----------------------------------------------------+                                          
      |                 +-------------------------------------------COMP:V-N(from)-------------------------------------------+                                          
      |                 |                 +-------------------------------------SUBJ:V-N-------------------------------------+                                          
      |                 |                 |                   +-----------------------OBJ:V-N----------------------+         |         +-------COMP:N-N(of)-------+     
      |                 |                 |                   |       +-----------COMP:N-N(of)----------+          |         |         |          +-MOD_ATT:N-ADJ-+     
      |          +MOD_AT+       +MOD_ATT:N+COMP:N-N(of)+      |       +COMP:N-N(+              +MOD_ATT:+COMP:N+   |         +-OBJ:V-N-+          |       +MOD_ATT+     
      |          |      |       |         |            |      |       |         |              |        |      |   |         |         |          |       |       |     
 In liver from adult __SP__ , oral administration of CFAM ( with a dosage of 1g/100g and a treatment period of 2 weeks ) decreases activity of __SP__ __NODE__ protein .
MOD_ATT:N-N (__SP__,adult)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,CFAM)
OBJ:V-N (with,week)
COMP:N-N(of) (dosage,1g/100g)
COMP:N-N(of) (dosage,period)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
COMP:V-N(In) (decrease,liver)
COMP:V-N(from) (decrease,__SP__)
SUBJ:V-N (decrease,administration)
OBJ:V-N (decrease,activity)
COMP:N-N(of) (activity,protein)
MOD_ATT:N-ADJ (protein,__SP__)
MOD_ATT:N-ADJ (protein,__NODE__)